FIELD: pharmacology.
SUBSTANCE: eye droplets for prevention and treatment of age-related nuclear cataract contain the following components: sodium chloride - 4.1 mg, sodium dihydrogen phosphate (monohydrate) - 4.6 mg, sodium hydrophosphate (ahydrous) - 4.74 mg, benzalkonium chloride - 0.2 mg, ondansetron hydrochloride dihydrate - 0.002-0.2 mg and water for injection - 1.0 ml.
EFFECT: application of the invention provides highly effective eye droplets for the conservative treatment and prevention of age-related nuclear cataract, taking into account the pathogenetically substantiated need for a differentiated approach to treatment of different types of age-related cataract.
1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF CONSERVATIVE TREATMENT AND PREVENTION OF NUCLEAR TYPE OF AGE CATARACT | 2009 |
|
RU2411926C2 |
| METHOD OF CONSERVATIVE TREATMENT AND PREVENTION OF CORTICAL TYPE OF AGE CATARACT | 2009 |
|
RU2418568C2 |
| EYE DROPS FOR TREATING AGE-RELATED NUCLEAR CATARACT | 2019 |
|
RU2720676C2 |
| IMPROVED EYE DROPS FOR PREVENTION AND TREATMENT OF EARLY MANIFESTATIONS OF AGE-RELATED NUCLEAR CATARACT | 2020 |
|
RU2748598C1 |
| METHOD FOR EXPERIMENTAL IN VIVO SIMULATION OF CORTICAL CATARACT | 2011 |
|
RU2553577C2 |
| METHOD FOR PREDICTION OF AGE-SPECIFIC CATARACT TYPE PRIOR TO CONTRACTION THEREOF | 2008 |
|
RU2371098C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AZAPENTACENE (VERSIONS) | 2014 |
|
RU2571279C1 |
| COMPOSITION FOR CATARACT TREATMENT | 2005 |
|
RU2298408C2 |
| ANTIOXIDANT AGENT FOR CATARACT TREATMENT | 2005 |
|
RU2297215C2 |
| THERAPY OF EARLY CATARACT | 2008 |
|
RU2367387C1 |
